Search Results 121-130 of 13186 for Tyrosine

  1. Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy In Previously Treated Advanced Or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations Or Other Genomic Alterations (MK-2870-004) - Mayo Clinic

    1.1. - Participants with genome mutations must have received 1 or 2 prior lines of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), ...

  2. Oncology (Medical) - Clinical trials

    This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...

  3. Midostaurin And Decitabine In Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia And FLT3 Mutation - Mayo Clinic

    ... tyrosine kinase 3 (FLT3) mutations. Midostaurin and decitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth ...

  4. Drugs and Supplements that Start with X - Mayo Clinic

    Explore a comprehensive list of prescription and over-the-counter medications starting with the letter “X” to learn about drug side effects, proper use and ...

  5. Clinical trials - Oncology (Medical)

    This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...

  6. Carbidopa and levodopa (route not applicable) - Mayo Clinic

    Tyrosine. Other Interactions. Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may ...

  7. Clinical trials - Oncology (Medical)

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  8. Hematology - Clinical trials

    This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...

  9. Clinical trials - Oncology (Medical)

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  10. Clinical trials - Oncology (Medical)

    This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...